Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Processa announced a research collaboration and exclusive option agreement with Generian Pharmaceuticals to advance an oral macrocyclic peptide FcRn antagonist program. The companies aim to develop oral alternatives to injectable treatments for IgG-mediated autoimmune diseases. The announcement disclosed neither human data for the peptide program nor financial terms; a separate BTK program received Phase 2 IND clearance.
HitGen reported consolidated revenue of RMB0.550 billion, up 48.73%, and attributable net income of RMB139.4 million for the nine months ended September 30, 2026. Attributable net income increased 50.11%. These are consolidated year-to-date figures rather than third-quarter-only results. The quarterly filing is unaudited and covers the year-to-date period.
C4 Therapeutics described a DNA-encoded library that incorporates its cereblon-binding ligand collection for target-first molecular glue discovery. The company reported known and novel VAV1 degrader hits as platform validation, while stating that it would not advance VAV1 without a partner. This is a discovery-platform update, not the clinical entry of a new drug candidate.
Kymera reported sustained IRF5 degradation and downstream biomarker changes in its Phase 1 healthy-volunteer study of KT-579, with no serious or severe adverse events observed. A Phase 1b lupus study, LUMORA, is planned for early 2027. These findings support human proof of mechanism, but healthy-volunteer data do not establish clinical benefit in patients.
Pharmaron reported consolidated revenue of RMB12.003 billion, up 19.01%, and attributable net income of RMB1,247.1 million for the nine months ended September 30, 2026. CDMO revenue rose 31.72%, while new CDMO orders increased more than 40%. The quarterly filing is unaudited and covers the year-to-date period.
Boji Medical reported consolidated revenue of RMB0.732 billion, up 25.24%, and attributable net income of RMB49.3 million for the nine months ended September 30, 2026. Attributable net income increased 124.95%, while net operating cash flow was negative RMB9.6 million over the period. The quarterly filing is unaudited and covers the year-to-date period.
An experimental H5N1 mRNA-LNP vaccine was tested in eight lactating dairy cows split between vaccinated and control groups. After two doses and mammary challenge, vaccination reduced peak viral RNA in milk by about 1,000-fold and lessened mastitis and fibrosis. This small animal study does not establish field effectiveness or human protection.
Monte Rosa announced that Novartis initiated a second Phase 2 study of the VAV1 molecular glue degrader MRT-6160, also called DDY391, in active moderate to severe psoriatic arthritis. The randomized, double-blind, placebo-controlled trial will assess efficacy, safety, tolerability, and dose response. The first patient visit triggers a $37.5 million milestone payment.
Quantum Design reported measuring about 650 dapsone crystals in 24 hours with an ELDICO ED-1. Its case study describes solving Form VI, a form not predicted by the cited CSP studies. This is a vendor-reported demonstration, not a general success-rate benchmark.
Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.
An October 27 preprint introduces GROND, an open-source tool that inserts dynamical scattering corrections between conventional electron diffraction processing and refinement. Tests across six structures improved refinement residuals and revealed previously unmodeled hydrogen atoms in small molecules. The work has not been peer reviewed, and performance on pharmaceutical samples needs separate validation.
Porton Pharma Solutions reported consolidated revenue of RMB2.765 billion, up 8.66%, and an attributable net loss of RMB112.1 million for the nine months ended September 30, 2026. The group posted an attributable loss of RMB112.1 million; impairment related to its discontinued Slovenia project affected earnings. The quarterly filing is unaudited and covers the year-to-date period.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
